OTCMKTS:CYDY

CytoDyn (CYDY) Stock Price, News & Analysis

CytoDyn logo
$0.23 0.00 (0.00%)
As of 11/18/2026 03:59 PM Eastern

About CytoDyn Stock (OTCMKTS:CYDY)

Advanced

Key Stats

Today's Range
$0.23
▼
$0.26
50-Day Range
$0.19
▼
$0.26
52-Week Range
$0.18
▼
$0.40
Volume
4.38 million shs
Average Volume
2.02 million shs
Market Capitalization
$347.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

CytoDyn Inc. is a biotechnology company focused on developing leronlimab, an investigational humanized monoclonal antibody that targets the CCR5 receptor. The company is based in Vancouver, Washington.

CytoDyn has studied leronlimab in clinical programs involving HIV and cancer, including research into its potential role in treating certain solid tumors. The company’s research has also explored other conditions in which CCR5 may be involved.

Leronlimab is an investigational product and is not an approved commercial therapy. CytoDyn’s activities center on its development and clinical research rather than the sale of marketed medicines.

AI Generated. May Contain Errors.

CytoDyn Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
8th Percentile Overall Score

CYDY MarketRank™: 
0.40845648604 of 5 stars

CytoDyn scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for CytoDyn.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CytoDyn is -7.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CytoDyn is -7.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about CytoDyn's valuation and earnings.
  • Percentage of Shares Shorted

    2.40% of the float of CytoDyn has been sold short.
  • Short Interest Ratio / Days to Cover

    CytoDyn has a short interest ratio ("days to cover") of 5.76.
  • Change versus previous month

    Short interest in CytoDyn has recently decreased by 0.31%, indicating that investor sentiment is improving.
  • Dividend Yield

    CytoDyn does not currently pay a dividend.

  • Dividend Growth

    CytoDyn does not have a long track record of dividend growth.

  • News Sentiment

    CytoDyn has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for CytoDyn this week, compared to 0 articles on an average week.
  • MarketBeat Follows

    3 people have added CytoDyn to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CytoDyn insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    1.00% of the stock of CytoDyn is held by insiders.

  • Percentage Held by Institutions

    5.06% of the stock of CytoDyn is held by institutions.

  • Read more about CytoDyn's insider trading history.
Receive CYDY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CytoDyn and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CYDY Stock News Headlines

CFA: Bank of America Said THIS
On January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.tc pixel
See More Headlines

CYDY Stock Analysis - Frequently Asked Questions

CytoDyn's stock was trading at $0.28 at the beginning of the year. Since then, CYDY stock has decreased by 19.6% and is now trading at $0.2250.

CytoDyn Inc. (OTCMKTS:CYDY) posted its earnings results on Wednesday, October, 14th. The biotechnology company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.04.

Shares of CYDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CytoDyn investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), NIO (NIO), Sorrento Therapeutics (SRNE) and Nokia (NOK).

Company Calendar

Last Earnings
10/14/2026
Today
11/19/2026
Next Earnings (Estimated)
1/14/2027
Fiscal Year End
5/31/2027

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:CYDY
Previous Symbol
NASDAQ:CYDY
CIK
1175680
Fax
N/A
Employees
14
Year Founded
2002

Profitability

EPS (Trailing Twelve Months)
($0.03)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$42.70 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-268.00%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.38
Quick Ratio
0.38

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.08) per share
Price / Book
-2.81

Miscellaneous

Outstanding Shares
1,545,030,000
Free Float
1,528,738,000
Market Cap
$347.63 million
Optionable
Not Optionable
Beta
1.71

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

This page (OTCMKTS:CYDY) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners